估算印度肺炎球菌结合疫苗、b型流感嗜血杆菌疫苗和轮状病毒疫苗的经济影响:国家与州级分析
研究从社会视角估算印度接种b型流感嗜血杆菌(Hib)、肺炎球菌结合疫苗(PCV)和轮状病毒疫苗(RVV)可避免的健康影响与成本。选取比哈尔、新德里、马哈拉施特拉和泰米尔纳德四个州,利用二手数据估算5岁以下死亡减少数并反推病例数,通过德尔菲调查和圆桌会议达成模型输入共识。结果显示扩大接种可每年节省超10亿美元并避免逾9万儿童死亡。
要点
- 每年可避免逾9万名儿童死亡。
- 约88%的成本节约来自肺炎球菌早亡导致的生产力损失。
核心结论
- 在印度引入Hib、PCV和RVV疫苗可为政府和家庭带来即时节省效益。
研究设计与样本
- 基于疾病负担、卫生系统强度和经济状况的差异,选取比哈尔、新德里、马哈拉施特拉和泰米尔纳德四个州。
- 使用二手数据来源估算各州5岁以下Hib、肺炎球菌和轮状病毒死亡减少数,并反推总病例数。
- 综合现有数据估算各州疾病负担、治疗成本、照护者生产力损失和疫苗覆盖率。
- 通过印度专家德尔菲调查和圆桌会议就模型输入达成共识。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To support vaccine decision-making we estimated from the societal perspective the potential health impact and costs averted through immunization with three vaccines - Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RVV). METHODS: Based on variability in disease burden, strength of health system and economic status, we selected four states in India: Bihar, New Delhi, Maharashtra and Tamil Nadu. We used secondary data sources to estimate the number of under-5 deaths averted from Hib, pneumococcus and rotavirus in each state and back-calculated the total cases averted. We synthesized available data to estimate the disease burden, treatment cost, caretaker productivity loss and vaccine coverage in each state. A Delphi Survey and roundtable among Indian experts was conducted to reach consensus on model inputs. RESULTS: By scaling up coverage of Hib, PCV and RVV, India could save over US$1 billion (uncertainty range: US$0.9-US$2.4 billion) in economic benefits and avert more than 90,000 needless child deaths each year. An estimated US$1 billion (US$0.9-US$2 billion) or 88% of the total amount of cost savings would be attributable to lost productivity due to premature pneumococcal death. Another US$112.8 million (US$105-297 million), or 10% of the total cost would be accounted by costs related to loss of productivity due to disability as a result of these diseases. Treatment costs of Hib, pneumococcal disease and rotavirus gastroenteritis, would account for US$8.4 million (US$4-12 million) or <1% of the total costs of these diseases. Finally, caretaker productivity loss from seeking care would represent US$1.5 million (US$ 1-4.9 million). Cost savings varied by vaccine, coverage scenarios and states. CONCLUSIONS: Hib, PCV and RVV vaccine introduction in India can result in immediate benefits to the government and households in terms of savings.
引用
- Constenla D, Liu T. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses. Vaccine. 2019. PMID: 31607600. doi:10.1016/j.vaccine.2019.09.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。